nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—PDE3A—cGMP effects—PDE3B—polycystic ovary syndrome	0.0465	0.115	CbGpPWpGaD
Anagrelide—PDE3A—Nitric oxide stimulates guanylate cyclase—PDE3B—polycystic ovary syndrome	0.0369	0.0914	CbGpPWpGaD
Anagrelide—Accidental injury—Metformin—polycystic ovary syndrome	0.0251	0.0422	CcSEcCtD
Anagrelide—Injury—Metformin—polycystic ovary syndrome	0.0176	0.0295	CcSEcCtD
Anagrelide—Renal impairment—Metformin—polycystic ovary syndrome	0.017	0.0285	CcSEcCtD
Anagrelide—Migraine—Metformin—polycystic ovary syndrome	0.0159	0.0267	CcSEcCtD
Anagrelide—Dehydration—Metformin—polycystic ovary syndrome	0.015	0.0252	CcSEcCtD
Anagrelide—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.0149	0.025	CcSEcCtD
Anagrelide—PDE3A—Platelet homeostasis—PDE3B—polycystic ovary syndrome	0.0144	0.0356	CbGpPWpGaD
Anagrelide—Influenza—Metformin—polycystic ovary syndrome	0.014	0.0234	CcSEcCtD
Anagrelide—Pancreatitis—Metformin—polycystic ovary syndrome	0.0137	0.023	CcSEcCtD
Anagrelide—Angina pectoris—Metformin—polycystic ovary syndrome	0.0136	0.0228	CcSEcCtD
Anagrelide—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.0134	0.0225	CcSEcCtD
Anagrelide—PDE3A—G alpha (s) signalling events—LHCGR—polycystic ovary syndrome	0.0124	0.0306	CbGpPWpGaD
Anagrelide—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.0118	0.0198	CcSEcCtD
Anagrelide—Rhinitis—Metformin—polycystic ovary syndrome	0.0112	0.0188	CcSEcCtD
Anagrelide—Hepatitis—Metformin—polycystic ovary syndrome	0.0112	0.0187	CcSEcCtD
Anagrelide—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.0111	0.0187	CcSEcCtD
Anagrelide—Oedema peripheral—Metformin—polycystic ovary syndrome	0.011	0.0185	CcSEcCtD
Anagrelide—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.011	0.0184	CcSEcCtD
Anagrelide—Eye disorder—Metformin—polycystic ovary syndrome	0.0104	0.0175	CcSEcCtD
Anagrelide—Cardiac disorder—Metformin—polycystic ovary syndrome	0.0104	0.0174	CcSEcCtD
Anagrelide—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.0101	0.0169	CcSEcCtD
Anagrelide—Chills—Metformin—polycystic ovary syndrome	0.01	0.0168	CcSEcCtD
Anagrelide—PDE3A—G alpha (s) signalling events—PDE3B—polycystic ovary syndrome	0.00993	0.0246	CbGpPWpGaD
Anagrelide—Malnutrition—Metformin—polycystic ovary syndrome	0.00972	0.0163	CcSEcCtD
Anagrelide—Flatulence—Metformin—polycystic ovary syndrome	0.00958	0.0161	CcSEcCtD
Anagrelide—Muscle spasms—Metformin—polycystic ovary syndrome	0.00935	0.0157	CcSEcCtD
Anagrelide—Vision blurred—Metformin—polycystic ovary syndrome	0.00916	0.0154	CcSEcCtD
Anagrelide—PDE3A—G alpha (s) signalling events—FSHR—polycystic ovary syndrome	0.00904	0.0224	CbGpPWpGaD
Anagrelide—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00902	0.0151	CcSEcCtD
Anagrelide—Malaise—Metformin—polycystic ovary syndrome	0.00877	0.0147	CcSEcCtD
Anagrelide—Syncope—Metformin—polycystic ovary syndrome	0.00872	0.0146	CcSEcCtD
Anagrelide—Palpitations—Metformin—polycystic ovary syndrome	0.00859	0.0144	CcSEcCtD
Anagrelide—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00855	0.0143	CcSEcCtD
Anagrelide—Hypertension—Metformin—polycystic ovary syndrome	0.00839	0.0141	CcSEcCtD
Anagrelide—Myalgia—Metformin—polycystic ovary syndrome	0.00828	0.0139	CcSEcCtD
Anagrelide—Chest pain—Metformin—polycystic ovary syndrome	0.00828	0.0139	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00822	0.0138	CcSEcCtD
Anagrelide—Discomfort—Metformin—polycystic ovary syndrome	0.00818	0.0137	CcSEcCtD
Anagrelide—PDE3A—G alpha (s) signalling events—ADRB3—polycystic ovary syndrome	0.00796	0.0197	CbGpPWpGaD
Anagrelide—Oedema—Metformin—polycystic ovary syndrome	0.00793	0.0133	CcSEcCtD
Anagrelide—Infection—Metformin—polycystic ovary syndrome	0.00788	0.0132	CcSEcCtD
Anagrelide—PDE3A—G alpha (s) signalling events—LHB—polycystic ovary syndrome	0.00787	0.0195	CbGpPWpGaD
Anagrelide—Shock—Metformin—polycystic ovary syndrome	0.00781	0.0131	CcSEcCtD
Anagrelide—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00778	0.0131	CcSEcCtD
Anagrelide—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00777	0.013	CcSEcCtD
Anagrelide—Skin disorder—Metformin—polycystic ovary syndrome	0.00771	0.0129	CcSEcCtD
Anagrelide—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00767	0.0129	CcSEcCtD
Anagrelide—Anorexia—Metformin—polycystic ovary syndrome	0.00756	0.0127	CcSEcCtD
Anagrelide—Hypotension—Metformin—polycystic ovary syndrome	0.00741	0.0124	CcSEcCtD
Anagrelide—PDE3A—G alpha (s) signalling events—SCT—polycystic ovary syndrome	0.00737	0.0182	CbGpPWpGaD
Anagrelide—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00723	0.0121	CcSEcCtD
Anagrelide—Paraesthesia—Metformin—polycystic ovary syndrome	0.00713	0.012	CcSEcCtD
Anagrelide—Dyspnoea—Metformin—polycystic ovary syndrome	0.00707	0.0119	CcSEcCtD
Anagrelide—Somnolence—Metformin—polycystic ovary syndrome	0.00705	0.0118	CcSEcCtD
Anagrelide—Dyspepsia—Metformin—polycystic ovary syndrome	0.00698	0.0117	CcSEcCtD
Anagrelide—Decreased appetite—Metformin—polycystic ovary syndrome	0.0069	0.0116	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00685	0.0115	CcSEcCtD
Anagrelide—Fatigue—Metformin—polycystic ovary syndrome	0.00684	0.0115	CcSEcCtD
Anagrelide—Constipation—Metformin—polycystic ovary syndrome	0.00679	0.0114	CcSEcCtD
Anagrelide—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—polycystic ovary syndrome	0.00665	0.0165	CbGpPWpGaD
Anagrelide—Feeling abnormal—Metformin—polycystic ovary syndrome	0.00654	0.011	CcSEcCtD
Anagrelide—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00649	0.0109	CcSEcCtD
Anagrelide—Urticaria—Metformin—polycystic ovary syndrome	0.0063	0.0106	CcSEcCtD
Anagrelide—Abdominal pain—Metformin—polycystic ovary syndrome	0.00627	0.0105	CcSEcCtD
Anagrelide—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—polycystic ovary syndrome	0.00606	0.015	CbGpPWpGaD
Anagrelide—CYP1A2—Tamoxifen metabolism—SULT2A1—polycystic ovary syndrome	0.00585	0.0145	CbGpPWpGaD
Anagrelide—PDE3A—Platelet homeostasis—GNAS—polycystic ovary syndrome	0.00578	0.0143	CbGpPWpGaD
Anagrelide—Asthenia—Metformin—polycystic ovary syndrome	0.00569	0.00956	CcSEcCtD
Anagrelide—Pruritus—Metformin—polycystic ovary syndrome	0.00561	0.00942	CcSEcCtD
Anagrelide—Diarrhoea—Metformin—polycystic ovary syndrome	0.00543	0.00911	CcSEcCtD
Anagrelide—Dizziness—Metformin—polycystic ovary syndrome	0.00525	0.00881	CcSEcCtD
Anagrelide—Vomiting—Metformin—polycystic ovary syndrome	0.00505	0.00847	CcSEcCtD
Anagrelide—Rash—Metformin—polycystic ovary syndrome	0.005	0.0084	CcSEcCtD
Anagrelide—Dermatitis—Metformin—polycystic ovary syndrome	0.005	0.00839	CcSEcCtD
Anagrelide—Headache—Metformin—polycystic ovary syndrome	0.00497	0.00834	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—GP1BB—polycystic ovary syndrome	0.00481	0.0119	CbGpPWpGaD
Anagrelide—Nausea—Metformin—polycystic ovary syndrome	0.00471	0.00791	CcSEcCtD
Anagrelide—CYP1A2—Estrogen Receptor Pathway—CYP1A1—polycystic ovary syndrome	0.00451	0.0112	CbGpPWpGaD
Anagrelide—PDE3A—G alpha (s) signalling events—ADRB2—polycystic ovary syndrome	0.0043	0.0106	CbGpPWpGaD
Anagrelide—PDE3A—G alpha (s) signalling events—GNAS—polycystic ovary syndrome	0.00399	0.00986	CbGpPWpGaD
Anagrelide—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—polycystic ovary syndrome	0.00382	0.00945	CbGpPWpGaD
Anagrelide—CYP1A2—Estrogen metabolism—CYP1A1—polycystic ovary syndrome	0.00348	0.0086	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PDE3B—polycystic ovary syndrome	0.00322	0.00797	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IGFBP1—polycystic ovary syndrome	0.00321	0.00793	CbGpPWpGaD
Anagrelide—CYP1A2—Xenobiotics—CYP1A1—polycystic ovary syndrome	0.0032	0.00791	CbGpPWpGaD
Anagrelide—CYP1A2—Tamoxifen metabolism—CYP1A1—polycystic ovary syndrome	0.00307	0.00761	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00304	0.00751	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—RACGAP1—polycystic ovary syndrome	0.00276	0.00683	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00276	0.00682	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00275	0.0068	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00269	0.00665	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00269	0.00665	CbGpPWpGaD
Anagrelide—PDE3A—G alpha (s) signalling events—POMC—polycystic ovary syndrome	0.00268	0.00664	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00254	0.00627	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00254	0.00627	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00249	0.00617	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—AKR1C3—polycystic ovary syndrome	0.00245	0.00605	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—CYP1A1—polycystic ovary syndrome	0.00237	0.00587	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00237	0.00587	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.0023	0.0057	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.0023	0.0057	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.0023	0.00569	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00224	0.00554	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP11A1—polycystic ovary syndrome	0.00224	0.00554	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP11A1—polycystic ovary syndrome	0.00221	0.00546	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00215	0.00533	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—AKR1C2—polycystic ovary syndrome	0.0021	0.00519	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00209	0.00517	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP17A1—polycystic ovary syndrome	0.00208	0.00515	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP17A1—polycystic ovary syndrome	0.00205	0.00508	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00204	0.00504	CbGpPWpGaD
Anagrelide—CYP1A2—Tryptophan metabolism—CYP19A1—polycystic ovary syndrome	0.00204	0.00504	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00203	0.00503	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00186	0.00461	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—SULT2A1—polycystic ovary syndrome	0.00186	0.0046	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00186	0.00459	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00185	0.00458	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP11A1—polycystic ovary syndrome	0.00181	0.00449	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.0017	0.0042	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—polycystic ovary syndrome	0.00169	0.00418	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP17A1—polycystic ovary syndrome	0.00169	0.00417	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PLAT—polycystic ovary syndrome	0.00169	0.00417	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00169	0.00417	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	0.00165	0.00407	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—polycystic ovary syndrome	0.00164	0.00406	CbGpPWpGaD
Anagrelide—CYP1A2—Tryptophan metabolism—CYP1A1—polycystic ovary syndrome	0.00164	0.00406	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—polycystic ovary syndrome	0.00164	0.00406	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.00163	0.00404	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NPB—polycystic ovary syndrome	0.00163	0.00403	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	0.00163	0.00402	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00161	0.00399	CbGpPWpGaD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—polycystic ovary syndrome	0.00158	0.00391	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00158	0.0039	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.00154	0.00381	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—CYP1A1—polycystic ovary syndrome	0.00154	0.0038	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.00151	0.00374	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00148	0.00367	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00147	0.00365	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00147	0.00363	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.00144	0.00357	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.00143	0.00354	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—SCT—polycystic ovary syndrome	0.00137	0.0034	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.00136	0.00336	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.00136	0.00336	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.00134	0.0033	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.00133	0.00328	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.00131	0.00324	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.00131	0.00324	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—GNAS—polycystic ovary syndrome	0.00129	0.0032	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.00127	0.00315	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00124	0.00305	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.0012	0.00297	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—INHBB—polycystic ovary syndrome	0.00117	0.0029	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.00117	0.00288	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00109	0.0027	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.00109	0.00269	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.00108	0.00266	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.00107	0.00265	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.00107	0.00264	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	0.00103	0.00255	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000996	0.00246	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	0.00099	0.00245	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000968	0.00239	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP11A1—polycystic ovary syndrome	0.000964	0.00238	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	0.000951	0.00235	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000936	0.00232	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000911	0.00225	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	0.000898	0.00222	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP17A1—polycystic ovary syndrome	0.000896	0.00222	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FST—polycystic ovary syndrome	0.000887	0.00219	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	0.000884	0.00219	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000882	0.00218	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000876	0.00217	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LHB—polycystic ovary syndrome	0.000866	0.00214	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000846	0.00209	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IGF1—polycystic ovary syndrome	0.000838	0.00207	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—AKT2—polycystic ovary syndrome	0.000838	0.00207	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.00082	0.00203	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000818	0.00202	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	0.000816	0.00202	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	0.000816	0.00202	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SCT—polycystic ovary syndrome	0.000812	0.00201	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	0.000802	0.00198	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000801	0.00198	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SERPINE1—polycystic ovary syndrome	0.000796	0.00197	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000774	0.00191	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—polycystic ovary syndrome	0.000769	0.0019	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000761	0.00188	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000754	0.00187	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000743	0.00184	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP19A1—polycystic ovary syndrome	0.000709	0.00175	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000704	0.00174	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	0.000699	0.00173	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000695	0.00172	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	0.000684	0.00169	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—INSR—polycystic ovary syndrome	0.000664	0.00164	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	0.000649	0.0016	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000631	0.00156	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000621	0.00154	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	0.000619	0.00153	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PGR—polycystic ovary syndrome	0.000615	0.00152	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000572	0.00141	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000572	0.00141	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP1A1—polycystic ovary syndrome	0.000572	0.00141	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	0.000564	0.00139	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000551	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—VEGFA—polycystic ovary syndrome	0.000548	0.00135	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000545	0.00135	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000532	0.00132	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000529	0.00131	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	0.000526	0.0013	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000503	0.00125	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NMNAT3—polycystic ovary syndrome	0.000503	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—POMC—polycystic ovary syndrome	0.0005	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRL—polycystic ovary syndrome	0.000499	0.00123	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000481	0.00119	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	0.00048	0.00119	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000473	0.00117	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	0.000469	0.00116	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LPCAT2—polycystic ovary syndrome	0.00046	0.00114	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SUOX—polycystic ovary syndrome	0.00046	0.00114	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	0.000454	0.00112	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000439	0.00109	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ISYNA1—polycystic ovary syndrome	0.000428	0.00106	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—POMC—polycystic ovary syndrome	0.000426	0.00105	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000418	0.00103	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	0.000418	0.00103	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NRG1—polycystic ovary syndrome	0.00041	0.00102	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	0.00039	0.000965	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	0.00037	0.000916	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TEAD2—polycystic ovary syndrome	0.000364	0.000899	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKR1C2—polycystic ovary syndrome	0.000364	0.000899	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000351	0.000869	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	0.00035	0.000865	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	0.000344	0.000851	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LEP—polycystic ovary syndrome	0.000344	0.000851	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000307	0.000759	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PNPLA2—polycystic ovary syndrome	0.000305	0.000754	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—POMC—polycystic ovary syndrome	0.000295	0.000731	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—INS—polycystic ovary syndrome	0.000294	0.000727	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SRD5A1—polycystic ovary syndrome	0.000289	0.000714	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000284	0.000703	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000284	0.000703	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—STAR—polycystic ovary syndrome	0.000276	0.000682	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	0.000272	0.000674	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.00027	0.000668	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	0.000246	0.000607	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	0.000234	0.000579	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	0.000232	0.000573	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	0.00022	0.000543	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000217	0.000538	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	0.000214	0.000528	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	0.000209	0.000516	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	0.000202	0.0005	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	0.000186	0.00046	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000186	0.000459	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	0.00018	0.000446	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	0.000174	0.00043	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	0.000167	0.000413	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	0.000166	0.00041	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	0.000165	0.000408	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	0.000164	0.000405	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	0.000156	0.000385	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	0.000153	0.000379	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TH—polycystic ovary syndrome	0.000133	0.000328	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	0.000129	0.000319	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—polycystic ovary syndrome	0.000128	0.000318	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	0.000121	0.0003	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	0.000108	0.000268	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	0.000103	0.000255	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	9.78e-05	0.000242	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	9.11e-05	0.000225	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	7.39e-05	0.000183	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	7.29e-05	0.00018	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—INS—polycystic ovary syndrome	7.25e-05	0.000179	CbGpPWpGaD
